Based on accumulating evidence, the American Diabetes Association (ADA)/European Association of the Study for Diabetes (EASD) recommends SGLT-2 inhibitors as elective therapy for T2DM [32]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.